AstraZeneca has taken a look at the competition emerging in the market for inflammatory bowel disease (IBD) therapies, and decided to shelve a project that had advanced in
AbbVie and Allergan’s $63 billion merger has been cleared by European regulators, who have approved the sell-off of pipeline gastrointestinal autoimmune diseases drug brazikumab to AstraZen
The venture capital arms of MSD and Amgen have provided $10 million in funding to Culmination Bio, a Utah start-up that aims to build the largest disease-agnostic patient
On 1st October, the roll-out of the National Contract Value Review (NCVR) process marked a pivotal moment in the trajectory of clinical research in the UK, introducing a standardised, natio